ISPOR PUBLISHES TASK FORCE REPORT #2 ON MULTIPLE CRITERIA DECISION ANALYSIS

Published Apr 5, 2016

Second Report Published in March/April Issue of Value in Health

Princeton, NJ—April 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a new Task Force Report, “Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force, ” in the March/April 2016 issue of Value in Health.  Many health care decisions are complex and require consideration of multiple, often conflicting objectives. They involve trade-offs that decision makers find challenging or on which they disagree. For instance, regulators often have to assess whether the benefits of a drug are sufficient to accept its safety risks. Lead author Kevin Marsh stated, “Decision makers, whether they are individuals, payers, or health ministries, often have difficulty processing and systematically evaluating potential treatment options and the numerous disparate factors impacting them. This set of techniques known as multiple criteria decision analysis (MCDA) can significantly improve the quality of complicated health care decisions.” This second MCDA Task Force Report builds on the foundational Report #1, “Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force,” published in the January/February 2016 issue of Value in Health. Co-author Maarten IJzerman explained, “While many MCDA methods exist, there is currently insufficient guidance on how to choose the right technique for a specific health care issue. The good practice guidelines provide an overview of the available MCDA methods and the principles to apply in choosing an appropriate method for a particular problem or decision.” The Task Force also developed a valuable checklist, the ISPOR MCDA Good Practice Guidelines Checklist, that outlines the steps for implementing MCDA. Finally, the capacity of MCDA to incorporate patients’ preferences on benefits and trade-offs of treatment options is an important benefit to all stakeholders.

###

Related Stories

Mapping the Open Source Revolution in Health Economics

Jun 17, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a groundbreaking study mapping the landscape of available open source models (OSMs) in health economics and revealing key insights into their distribution, characteristics, and applications.

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×